Zydus Cadila gets USFDA nod to market generic HIV treatment tablets
Drug firm Zydus Cadila Friday said it has received final approval from the US health regulator to market generic Abacavir and Lamivudine tablets used for treatment of a type of HIV infection.
Drug firm Zydus Cadila Friday said it has received final approval from the US health regulator to market generic Abacavir and Lamivudine tablets used for treatment of a type of HIV infection.
The company also said in the regulatory filing that it had received final approval from the United States Food and Drug Administration (USFDA) to market generic Fondaparinux Sodium injection. The approval from the USFDA is for Abacavir and Lamivudine tablets USP in the strength of 600 mg/300 mg, Zydus Cadila said.
The tablets are used with other antiretroviral medicines to treat human immunodeficiency virus-type 1 (HIV-1) infection that causes acquired immune deficiency syndrome (AIDS), it added.
"The product will be manufactured at the group's formulations manufacturing facility at special economic zone (SEZ), Ahmedabad," Zydus Cadila said.
The nod for the Fondaparinux Sodium injection USP is in the strengths of 2.5 mg/0.5 mL, 5 mg/0.4 mL, 7.5 mg/0.6 mL and 10 mg/0.8 mL single-dose, it added.
Fondaparinux Injection is used to treat blood clots in deep veins and the lungs. It can also be used to prevent blood clots in patients undergoing certain types of surgeries, Zydus Cadila said. "It will be manufactured at a partner's manufacturing site," it added.
The group now has more than 230 approvals and has so far filed over 330 abbreviated new drug applications (ANDAs) since the commencement of its filing process, Zydus Cadila said.
Watch This Zee Business Video Here:
Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 357.80 per scrip on BSE, down 0.54 per cent from their previous close.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Power of Compounding: How many years will it take to reach Rs 3 crore corpus if your monthly SIP is Rs 4,000, Rs 5,000, or Rs 6,000
Power of Compounding: Salary Rs 25,000 per month; is it possible to create over Rs 2.60 crore corpus; understand it through calculations
Reduce Home Loan EMI vs Reduce Tenure: Rs 75 lakh, 25-year loan; which option can save Rs 25 lakh and 64 months and how? Know here
Top 7 Large and Mid Cap Mutual Funds with Best SIP Returns in 5 Years: No. 1 fund has turned Rs 15,000 monthly SIP investment into Rs 20,54,384; know about others
New Year Pick by Anil Singhvi: This smallcap stock can offer up to 75% return in long term - Check targets
PSU Oil Stocks: Here's what brokerage suggests on these 2 largecap, 1 midcap scrips - Buy, Sell or Hold?
02:35 PM IST